Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04441931 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3832479 (LY-CoV016) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT04441931 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 26 participants.
The verdict
NCT04441931, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn more about the safety of LY3832479 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3832479 is in the bloodstream and how long it takes the body to eliminate it. Participation could last up to 16 weeks and may include up to 10 visits to the study center.
Interventions
- DRUG Placebo
- DRUG LY3832479
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-06-19 |
| Est. Completion | 2020-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04441931
The ClinicalTrials.gov registry entry for NCT04441931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04441931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04441931 about?
NCT04441931 is a clinical study titled "A Study of LY3832479 (LY-CoV016) in Healthy Participants". The main purpose of this study is to learn more about the safety of LY3832479 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3832479 is in the bloodstream and how long it takes the body to eliminate it. Participation could last up to 16 weeks an...
What is the current status of trial NCT04441931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2020-06-19. Estimated completion is 2020-10-02.
What interventions are being tested in trial NCT04441931?
The interventions under investigation include: Placebo (DRUG), LY3832479 (DRUG).
Who is sponsoring clinical trial NCT04441931?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.